6.33

0.94% -0.06

Pre-market: 6.34 0.010 +0.16%

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $6.33, with a volume of 1.68M. It is down -0.94% in the last 24 hours and up +46.87% over the past month. Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Previous Close:

$6.39

Open:

$6.39

24h Volume:

1.68M

Relative Volume:

0.62

Market Cap:

$1.82B

Revenue:

$9.77M

Net Income/Loss:

$-109.00M

P/E Ratio:

-17.56

EPS:

-0.3604

Net Cash Flow:

$-93.83M

1W Performance:

-1.09%

1M Performance:

+46.87%

6M Performance:

+27.62%

1Y Performance:

+162.66%

1-Day Range:

$6.205

$6.4096

1-Week Range:

$6.11

$6.72

52-Week Range:

$1.845

$6.76

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	6.33	1.82B	9.77M	-109.00M	-93.83M	-0.3604
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-25	Initiated	Raymond James	Strong Buy
Jul-11-25	Initiated	BofA Securities	Buy
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

May 02, 2026

Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday - MarketBeat

May 02, 2026

May 01, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2026

Five new Taysha hires get 188,000 stock units under Nasdaq rule - Stock Titan

May 01, 2026

Apr 29, 2026

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 - Investing News Network

Apr 29, 2026

Biotech Taysha pairs its Q1 results with a corporate update on May 6 - Stock Titan

Apr 29, 2026

Earnings update from Taysha Gene Therapies expected next week - Traders Union

Apr 29, 2026

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call ... - Caledonian Record

Apr 29, 2026

Apr 28, 2026

Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge? - Yahoo Finance

Apr 28, 2026

Apr 27, 2026

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting - Investing News Network

Apr 27, 2026

Taysha to present preclinical data on Rett syndrome gene therapy By Investing.com - Investing.com Canada

Apr 27, 2026

Taysha Gene Therapies Reports Preclinical Data Supporting TSHA-102 Gene Therapy for Rett Syndrome at ASGCT Annual Meeting - Quiver Quantitative

Apr 27, 2026

Taysha Gene Therapies to Present New Preclinical Data - GlobeNewswire

Apr 27, 2026

Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN

Apr 27, 2026

Apr 26, 2026

Taysha Gene Therapies Shares Surge After FDA Grants Breakthrough Therapy Status - MSN

Apr 26, 2026

Apr 23, 2026

Taysha Gene Therapies stock hits 52-week high at 6.7 USD - Investing.com India

Apr 23, 2026

Apr 22, 2026